AVEO's Tivozanib Demonstrates Anti-Tumor Activity in Engineered Lung Tumors Exhibiting Treatment Resistant Mutations

Source :: Business Wire. July 31, 2009
Publication Year :: 2009
Abstract: Preclinical Data Presented at International Lung Conference; Underscores Tivozanib Potency CAMBRIDGE, Mass. -- AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize [...]

Subjects :: Endothelial growth factors -- Genetic aspects
Tumors -- Drug therapy -- Genetic aspects
Lung tumors -- Drug therapy -- Genetic aspects
Cancer -- Care and treatment
Pharmaceutical industry -- Genetic aspects
Business
Business, international

Tools